Skip to main content

Advertisement

SpringerLink
Log in

Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6

  • Research
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Early-stage Hodgkin lymphoma has become one of the most curable hematologic malignancies. Depending upon the disease location, possible toxicities, and patient preference, chemotherapy alone with ABVD remains an accepted treatment modality for this disease. There remains a paucity of data regarding the longitudinal trajectory of health-related quality of life (HRQoL) in patients treated for HL. The impact of disease and treatment on HRQoL is increasingly important to understand as the number of long-term survivors increases. We report the longitudinal HRQoL using data prospectively collected from diagnosis up to 10 years post-treatment in the ABVD arm of the HD.6 randomized controlled trial for early-stage HL patients (N=169). We analyzed HRQoL using the EORTC QLQ-C30 collected at baseline, 3 months, 6 months, and 12 months after completion of chemotherapy and yearly up to year 10. Clinically and statistically significant improvements were noted for specific domains including emotional (3 months post-treatment), social (12 months post-treatment) and financial functioning (2 years post-treatment), and the specific symptom of fatigue (6 months post-treatment) during the follow-up period. To our knowledge, this is the first prospective, longitudinal analysis of HRQoL specifically among patients with early-stage HL treated with ABVD therapy alone. Although improvements were noted, sustained clinically and statistically significant improvements were noted only in select symptoms emphasizing the need to better understand and optimize HRQoL among this patient group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607

    Article  CAS  PubMed  Google Scholar 

  2. André MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response–adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794

    Article  PubMed  Google Scholar 

  3. Hoppe RT, Advani RH, Ai WZ et al (2020) Hodgkin lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. J Natl Compr Canc Netw 18(6):755–781

    Article  PubMed  Google Scholar 

  4. Surveillance, Epidemiology and End Results Program. SEER Fact Sheets: Hodgkin’s lymphoma. https://seer.cancer.gov/statfacts/html/hodg.html. Accessed June 10, 2021.

  5. International Health Conference Constitution of the World Health Organization. Bull World Health Organ. 2002;80(12):983-4.

  6. Linendoll N, Saunders T, Burns R et al (2016) Health-related quality of life in Hodgkin lymphoma: a systematic review. Health Qual Life Outcomes 14(1):114

    Article  PubMed  PubMed Central  Google Scholar 

  7. Loge JH, Abrahamsen AF, Ekeberg O et al (1999) Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. Ann Oncol 10(1):71–77

    Article  CAS  PubMed  Google Scholar 

  8. Mols F, Vingerhoets AJ, Coebergh JW et al (2006) Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: a population-based study. Eur J Cancer 42(16):2794–2801

    Article  PubMed  Google Scholar 

  9. Ganz PA, Moinpour CM, Pauler DK et al (2003) Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 21(18):3512–3519

    Article  PubMed  Google Scholar 

  10. Heutte N, Flechtner HH, Mounier N et al (2009) Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 10(12):1160–1170

    Article  PubMed  Google Scholar 

  11. Kreissl S, Muller H, Goergen H et al (2020) Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin study group. J Clin Oncol 38(25):2839–2848

    Article  PubMed  Google Scholar 

  12. Meyer RM, Gospodarowicz MK, Connors JM et al (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23(21):4634–4642

    Article  CAS  PubMed  Google Scholar 

  13. Meyer RM, Gospodarowicz MK, Connors JM et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366(5):399–408

    Article  CAS  PubMed  Google Scholar 

  14. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376

    Article  CAS  PubMed  Google Scholar 

  15. The EORTC QLQ-C30 scoring manual. Available https://qol.eortc.org/manuals/. Accessed April 14.

  16. Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144

    Article  CAS  PubMed  Google Scholar 

  17. Cocks K, King MT, Velikova G et al (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96

    Article  PubMed  Google Scholar 

  18. Osoba D, Bezjak A, Brundage M et al (2005) Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41(2):280–287

    Article  PubMed  Google Scholar 

  19. Nolte S, Liegl G, Petersen MA et al (2019) General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer 107:153–163

    Article  CAS  PubMed  Google Scholar 

  20. Ilie G, Bradfield J, Moodie L et al (2019) The role of response-shift in studies assessing quality of life outcomes among cancer patients: a systematic review. Front Oncol:9

  21. Courneya KS, Sellar CM, Stevinson C et al (2009) Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 27(27):4605–4612

    Article  PubMed  Google Scholar 

  22. Oldervoll LM, Kaasa S, Knobel H et al (2003) Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors--results from a pilot study. Eur J Cancer 39(1):57–63

    Article  CAS  PubMed  Google Scholar 

  23. Crombie JL, LaCasce AS (2019) Current considerations in AYA Hodgkin lymphoma. Br J Haematol 184(1):72–81

    Article  PubMed  Google Scholar 

  24. Behringer K, Muller H, Gorgen H et al (2013) Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group. British Journal of Cancer 108(1):49–57

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Dr. HM is the recipient of a research early career award from Hamilton Health Sciences. Dr. JNW is supported in part by the National Cancer Institute of the National Institutes of Health under award numbers: U10CA180820 and UG1CA233320. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding

The Canadian Cancer Trials Group is supported by funds from the Canadian Cancer Society (707213) and by the National Cancer Institute, National Institutes of Health (CA180863).

Author information

Authors and Affiliations

  1. Department of Oncology, McMaster University, 699 Concession St, Hamilton, ON, L8V 5C2, Canada

    Hira Mian, Ralph Meyer & Jonathan Sussman

  2. Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre/UHN, University of Toronto, Toronto, Canada

    Jolie Ringash

  3. Department of Radiation Oncology, University of Toronto, Toronto, Canada

    Jolie Ringash

  4. Canadian Cancer Trials Group, Department of Medicine, Queen’s University, Kingston, Canada

    Annette E. Hay

  5. Canadian Cancer Trials Group, Department of Pathology & Molecular Medicine, Queen’s University, Kingston, Canada

    Lois Shepherd

  6. Canadian Cancer Trials Group, Queen’s University, Kingston, Canada

    Marina Djurfeldt & Joseph Pater

  7. Northwestern University, Feinberg School of Medicine, Illinois, USA

    Jane N. Winter

  8. Canadian Cancer Trials Group, Department of Public Health Sciences and Department of Mathematics and Statistics, Queen’s University, Kingston, Canada

    Bingshu E. Chen

  9. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

    Anca Prica

Authors
  1. Hira Mian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jolie Ringash
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ralph Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annette E. Hay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lois Shepherd
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marina Djurfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jane N. Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jonathan Sussman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joseph Pater
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bingshu E. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Anca Prica
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design: RM, Data collection: BC. Analysis and interpretation of data: HM. JR, JP, AH, JS, AP, LS, MD. Manuscript writing: all authors. Approval of final article: all authors. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Hira Mian.

Ethics declarations

Conflict of interest

HM: Consultancy/Honoraria fees from Celgene, Takeda, Janssen, Amgen, Sanofi, Research funding Janssen. BC: None. JR: None. RM: None. AH: Research funding from Merck, Seattle Genetics, AbbVie, Roche-Genentech, Karyopharm. LS: None. MD: None. JP: None. JS: None. AP: Honoraria from Astra-Zeneca and Kite Gilead. JNW: Merck, honoraria and research support.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mian, H., Ringash, J., Meyer, R. et al. Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6. Support Care Cancer 31, 256 (2023). https://doi.org/10.1007/s00520-023-07717-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00520-023-07717-3

Keywords

Search

Navigation